The SERCA pump as a therapeutic target: Making a "smart bomb" for prostate cancer

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 21-29

  Denmeade, Samuel R ^a,b   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

Apoptosis; Calcium; Endoplasmic reticulum; Prodrug; SERCA; Stress response; Thapsigargin

Indexed keywords

8 O [12 (LEUCINOYLAMINO)DODECANOYL] 8 O DEBUTANOYLTHAPSIGARGIN; ADENOSINE TRIPHOSPHATASE (CALCIUM); DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PEPTIDE; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEINASE; SARCOPLASMIC ENDOPLASMIC ADENOSINE TRIPHOSPHATASE (CALCIUM); THAPSIGARGIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; LACTONE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SESQUITERPENE; THAPSIGARGICIN;

APOPTOSIS; CANCER CELL; CANCER LOCALIZATION; CANCER THERAPY; CELL DEATH; CELL METABOLISM; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; EVALUATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; NONHUMAN; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SARCOPLASMIC RETICULUM; STRESS; DRUG EFFECT; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

APOPTOSIS; CALCIUM-TRANSPORTING ATPASES; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; HUMANS; LACTONES; MALE; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SESQUITERPENES; THAPSIGARGIN;

EID: 24644432531     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.1.1505     Document Type: Review

References (97)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12.
2. 1 check-point control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001; 61:6372-6.
3. Berges RS, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1:473-80.
4. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34:646-53.
5. Rao RV, Hermel E, Castro-Obregon S, del Rio G, Ellerby LM, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 2001; 276:33809-74.
6. Rutkowski DT, Kaufman RJ. A trip to the ER: Coping with stress. Trends Cell Biol 2004; 14:20-8.
7. Ma Y, Hendershot LM The role of the unfolded protein response in tumour development: Friend or foe? Nat Rev Cancer 2004; 4:966-77.
8. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994; 54:6167-75.
9. Furuya Y, Isaacs JT. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 1994; 25:301-9.
10. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95:990-1000.
11. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003; 22:8608-18.
12. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature Cell Biol 2000; 2:326-32.
13. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110:1389-98.
14. Ma Y, Hendershot LM. The mammalian endoplasmic reticulum as a sensor for cellular stress. Cell Stress Chaperones 2002; 7:222-9.
15. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397:271-4.
16. Liu CY, Schroder M, Kaufman RJ. Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem 2000; 275:24881-5.
17. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PERK, involved in translational control. Mol Cell Biol 1998; 18:7499-509.
18. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6:1099-108.
19. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, Kaufman RJ. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001; 7:1165-76.
20. Brewer JW, Diehl JA. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci USA 2000; 97:12625-30.
21. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6:1099-108.
22. Ma Y, Hendershot LM. Delineation of the negative feedback regulatory loop that controls protein translation during ER stress. J Biol Chem 2003; 278:34864-73.
23. Jiang HY, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR, Wek RC. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. Mol Cell Biol 2003; 23:5651-63.
24. Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell 2002; 3:99-111.
25. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell 1999; 10:3787-99.
26. Yoshida H, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol Cell Biol 2000; 20:6755-67.
27. Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, Brown MS, Goldstein JL. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell 2000; 6:1355-64.
28. Yoshida H, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K. Endoplasmic reticulum stress-induced formation of transcription factor complex ERSF including NF-Y (CBF) and activating transcription factors 6alpha and 6beta that activates the mammalian unfolded protein response. Mol Cell Biol 2001; 21:1239-48.
29. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107:881-91.
30. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, Clark SG, Ron D. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002; 415:92-6.
31. Sidrauski C, Walter P. The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response. Cell 1997; 90:1031-9.
32. Tirasophon W, Welihinda AA, Kaufman RJ. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev 1998; 12:1812-24.
33. Sidrauski C, Cox JS, Walter P. tRNA ligase is required for regulated mRNA splicing in the unfolded protein response. Cell 1996; 87:405-13.
34. Mori K, Ogawa N, Kawahara T, Yanagi H, Yura T. mRNA splicing-mediated C-terminal replacement of transcription factor Hac1p is required for efficient activation of the unfolded protein response. Proc Natl Acad Sci USA 2000; 97:4660-5.
35. Kawahara T, Yanagi H, Yura T, Mori K. Endoplasmic reticulum stress-induced mRNA splicing permits synthesis of transcription factor Hac1p/Ern4p that activates the unfolded protein response. Mol Cell Biol 1997; 8:1845-62.
36. Vander Heiden MG, Thompson CB. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1:E209-16.
37. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001; 26:61-6.
38. 2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 2002; 277:20301-8.
39. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 2002; 277:9219-25.
40. 2+: A control point for apoptosis. Science 2003; 300:135-9.
41. Wang XZ, Lawson B, Brewer JW, Zinszner H, Sanjay A, Mi LJ, Boorstein R, Kreibich G, Hendershot LM, Ron D. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol 16:4273-80.
42. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001; 21:1249-59.
43. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002; 277:34287-94.
44. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, Bredesen DE, Ellerby HM. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 2002; 277:21836-42.
45. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, Manabe T, Yamagishi S, Bando Y, Imaizumi K, Tsujimoto Y, Tohyama M. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and A-induced cell death. J Cell Biol 2004; 165:347-56.
46. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000; 150:887-94.
47. Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 2003; 162:59-69.
48. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol 2003; 160:1115-27.
49. Granville DJ, Carthy CM, Jiang H, Shore GC, McManus BM, Hunt DW. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 1998; 437:5-10.
50. Maatta J, Hallikas O, Welti S, Hilden P, Schroder J, Kuismanen E. Limited caspase cleavage of human BAP31. FEBS Lett 2000; 484:202-6.
51. Ng FW, Shore GC. Bel-XL cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor. J Biol Chem 1998; 273:3140-3
52. Wuytack F, Raeymaekers L, Missiaen L. Molecular physiology of the SERCA and SPCA pumps. Cell Calcium 2002; 32:279-305.
53. East JM. Sarco(endo)plasmic reticulum calcium pumps: Recent advances in our understanding of structure/function and biology (review). Mol Membr Biol 2000; 17:189-200.
54. Toyoshima C, Nakasako M, Nomura H, Ogawa H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 2000; 405:647-55.
55. 2+-ATPase in various physiological states. Ann NY Acad Sci 2003; 986:1-8.
56. 2+ and intracellular Ca2+ stores in induction and suppression of apoptosis in S49 cells. Am J Physiol 1997; 272:C1241-9.
57. He H, Lam M, McCormick TS, Distelhorst CW. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J Cell Biol 1997; 138:1219-28.
58. Dowd DR, MacDonald PN, Komm BS, Haussler MR, Miesfeld RL. Stable expression of the calbindin-D28K complementary DNA interferes with the apoptotic pathway in lymphocytes. Mol Endocrinol 1992; 6:1843-8.
59. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997; 33:201-7.
60. Ma TS, Mann DL, Lee JH, Gallinghouse GJ. SR compartment calcium and cell apoptosis in SERCA overexpression. Cell Calcium 1999; 26:25-36.
61. Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 2000; 43:303-17.
62. 2+ permeability. Biochem Pharmacol 1989; 38:3995-4003.
63. 2+ permeability of the plasma membrane. Comparison of the effects of thapsigargin, 2,5-di-(tert-butyl)-1,4- hydroquinone, and cyclopiazonic acid in rat thymic lymphocytes. J Biol Chem 1991; 266:20856-62.
64. 2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002; 366:831.
65. 2+. J Biol Chem 2001; 276:46905-11.
66. Voss JC, Mahaney JE, Thomas DD. Mechanism of Ca-ATPase inhibition by melittin in skeletal sarcoplasmic reticulum. Biochemistry 1995; 34:930-9.
67. Sagara Y, Inesi G. Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. J Biol Chem 1991; 266:13503-6.
68. 2+-ATPase. Proc Natl Acad Sci USA 1990; 87:2466-70.
69. 2+-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995; 270:11731-4.
70. Rasmussen U, Brogger Christensen S, Sandberg F. Thapsigargine and thapsigargicine, two new histamine liberators from Thapsia garganica L. Acta Pharm Suec 1978; 15:133-40.
71. Christensen SB, Norup E, Rasmussen U. Chemistry and structureactivity relationship of the histamine secretagogue Thapsigargin and related compounds. In: Krosgard-Larsen, ed. Natural Product Drug Development. Copenhagen: Munksgaard 1993:405-18.
72. Lam M, Dubyak G, Distelhorst CW. Effect of glucocorticosteroid treatment on intracellular calcium homeostasis in mouse lymphoma cells. Mol Endocrinol 1993; 7:686-93.
73. Kaneko Y, Tsukamoto A. Thapsigargin-induced persistent intracellular calcium pool depletion and apoptosis in human hepatoma cells. Cancer Lett 1994; 79:147-55.
74. 2+ influx. Nature (Lond.) 1993; 364:809-14.
75. + current by means of a phosphatase and a diffusible messenger. Nature 1993; 364:814-8.
76. 2+ in individual cells undergoing apoptosis. Cell Calcium 1999; 1:19-28.
77. Jackisch C, Hahm H, Tombal B, McCloskey D, Butash K, Davidson N, Denmeade SR. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res 2000; 6:2844-50.
78. i) is consistently required to induce the execution phase of apoptosis. Cell Death and Differentiation 2002; 9:561-73.
79. Tonks NK, Cohen P. Calcineurin is a calcium ion-dependent, calmodulin-stimulated protein phosphatase. Biochim Biophys Acta 1983; 747:191-3.
80. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284:339-43.
81. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304:437-44.
82. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56.
83. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292:727-30.
84. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90:405-13.
85. Akiyama K, Nakamura T, Iwanaga S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 1987; 225:168-72.
86. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194:755-63.
87. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichy-motrypsin. Clin Chem 1991; 37:1618-25.
88. Denmeade SR, Isaacs JT. Enzymatic activation of pro drugs by prostate specific antigen: Targeted therapy for metastatic prostate cancer. The Cancer Journal from Scientific American 1998; 4:S15-21.
89. Otto A, Bar J, Birkenmeier G. Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J Urol 1998; 159:297-303.
90. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57:4924-30.
91. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001; 48:1-6.
92. Christensen SB, Andersen A, Kromann H, et al. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999; 7:1273-80.
93. Jakobsen CM, Denmeade SR, Isaacs JT, Gady AM, Olsen CE, Christensen SB. Design, synthesis and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001; 44:4696-703.
94. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998; 58:2537-40.
95. Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 2000; 45:80-3.
96. Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther 2004; 3:1439-50.
97. Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2004; 3:551-8.